Exploring challenges in the management and treatment of inclusion body myositis.

ABSTRACT:

Purpose of review

This review provides an overview of the management and treatment landscape of inclusion body myositis (IBM), while highlighting the current challenges and future directions.

Recent findings

IBM is a slowly progressive myopathy that predominantly affects patients over the age of 40, leading to increased morbidity and mortality. Unfortunately, a definitive cure for IBM remains elusive. Various clinical trials targeting inflammatory and some of the noninflammatory pathways have failed. The search for effective disease-modifying treatments faces numerous hurdles including variability in presentation, diagnostic challenges, poor understanding of pathogenesis, scarcity of disease models, a lack of validated outcome measures, and challenges related to clinical tri

SUBMITTER: Skolka MP 

PROVIDER: S-EPMC10552844 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature